DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20212089

Systemically administered central nervous system drugs induced ocular side effects: a review

Vijayakumar A. R., Prabu Daniel Epison, Kabeera Begum A., Abirami V. P., Ajmal Hussain, Abdul Azeez Kader, Ansar Ali Abdunnasir

Abstract


Several systemic drugs have reported ocular and visual side effects that affect patient management. It is imperative to be familiar with the associated side effects which can be mild or transient and may seriously threaten vision. This article deals briefly with the mechanisms and reasons that account for the impact that systemically administered central nervous system (CNS) drugs can exert on the visual or ocular system. The eye care practitioner can be instrumental in detecting and reporting ocular side effects, advising patients and collaborating with other members of the patient’s healthcare team. One of the difficulties include becoming familiar with the countless systemic medications prescribed to patients. Another is being able to correlate a particular side effect with a suspected drug. Several of the ocular adverse effects such as glaucoma, cataract, blurred vision, color vision, optic neuritis, maculopathy, dry eye, etc., are vision threatening and often patients fail to recognize or describe the symptoms appropriately. Therefore, physicians and paramedical members like staff nurses, clinical pharmacists and other members must make adequate observations while recommending these drugs to patients.


Keywords


Systemic administration, Ocular toxicity, Central nervous system drugs, Alcohol, Epileptics, CNS stimulants

Full Text:

PDF

References


Deichmann WB, Henschler D, Holmstedt B, Keil G. What is there that is not poison? A study of the third defense by Paracelsus. Archives of Toxicology. 1986;58:207-13.

Jaanus SD, Bartlett JD, Hiett, JA. Ocular effects of systemic drugs. In: Bartlett JD and Jaanus SD, eds. Clinical Ocular Pharmacology, 3rd ed. Boston: Butterworth-Heinemann. 1995;957-1006.

Koneru PB, Lien EJ, Koda RT. Review: Oculotoxicities of systemically administered drugs. J Ocular Pharm. 1886;2(4):385-99.

Mycek MJ, Harvey RA, Champe PC. Lippincott’s Illustrated Reviews: Pharmacology, 2nd ed. Philadelphia: Lippincott-Raven. 1997.

Muchnick BG. The ocular manifestations of systemic drugs. Optom Today. 1998;44-52.

Bartlett JD. Ophthalmic toxicity by systemic drugs. In: GCY Chiou, ed. Ophthalmic Toxicology, 2nd ed. Michigan: Taylor and Francis. 1999;225-83.

Hamburger E: Identification and treatment of barbiturate abusers, JAMA. 1965;193:143-4.

Homma K, Wakakura M, Ishikawa S. A case of phenobarbital-induced optic neuropathy, Neuro-Ophthalmol. 1989;9(6):357-9.

Levy DL, Lipton RB, Holzman PS. Smooth pursuit eye movements: effects of alcohol and chloral hydrate, J Psychiatr Res. 1981;16:1-11.

Mowry JB, Wilson GA. Effect of exchange transfusion in chloral hydrate overdose, Vet Human Toxicol. 1983;25(Suppl 1):15.

Kavet R, Nauss KM. The toxicity of inhaled methanol vapors. Critical reviews in toxicology. 1990;21:21-50.

Sharpe JA, Hostovsky M, Bilbao JM, Rewcastle NB. Methanol optic neuropathy: a histopathological study. Neurology. 1982;32:1093-100.

Lantz CL, Sipe GO, Wong EL, Majewska AK, Medina AE. Effects of Developmental Alcohol Exposure on Potentiation and Depression of Visual Cortex Responses. Alcohol ClinExp Res. 2015;39:1434-42.

Wang S, Wang JJ, Wong TY. Alcohol and eye disease, SurvOphthalmol. 2008;53(5):512-25.

Kanthan GL, Mitchell P, Burlutsky G. Alcohol consumption and the long-term incidence of cataract and cataract surgery: the blue mountain eye study, Am J Ophthalmol. 2010;150(3):434-40.

Knudtson MD, Klein R, Klein BE. Alcohol consumption and the 15-year cumulative incidence of age-related macular degeneration. Am J Ophthalmol. 2007;143(6):1026-9.

Brent J, Mc Martin K, Phillips S. Fomepizole for the treatment of methanol poisoning, N Engl J Med. 2001;344(6):424-9.

Dethlefs R, Naragi S. Ocular manifestations and complications of acutemethyl alcohol intoxication, Med J Aust. 1978;4(10):483-5.

Barceloux DG, Bond GR, Krenzelok EP. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning, J Toxicol Clin Toxicol. 2002;40(4):415-6.

Desai T, Sudhalkar A, Vyas U. Methanol poisoning: predictors ofvisual outcomes, JAMA Ophthalmol. 2013;131(3):358-64.

Horiguchi J, Inami Y. Effect of clonazepam on neuroleptic-induced oculogyric crisis. ActaPsychiatr Scand. 1989;80:521-3.

Hilton EJ, Hosking SL, Betts T. The effect of antiepileptic drugs on visual performance. Seizure, 2004;13:113-28.

Veerapandiyan A, Gallentine WB, Winchester SA, Baker J, Kansagra SM, Mikati MA. Oculogyric crises secondary to lamotrigineoverdosage. Epilepsia. 2011;52:4-6.

Marino D, Malandrini A, Rocchi R. Transient “sicca syndrome” during phenobarbital treatment, NeurolSci. 2011;300(1–2):164.

Tripathi RC, Tripathi BC. The Eye. In Riddell RH, editor: Pathology of Drug-Induced and Toxic Diseases, New York, 1982, Churchill Livingstone. 1982;377-450.

Bullock JD, Albert DM. Flecked retina. Arch Ophthalmol. 1975;93:26-31.

Lockwood AJ, Yang YF. Nitrous oxide inhalation anaesthesia in the presence of intraocular gas can cause irreversible blindness. Br Dent J. 2008;204(5):247-8.

Fenwick PB, Stone SA, Bushman J. Changes in the pattern reversalvisual evoked potential as a function of inspired nitrous oxideconcentration, Electroencephalogr Clin Neurophysiol. 1984;57:178-83.

Starte JM, Fung AT, Kerdraon YA. Ketamine-associated corneal edema. Cornea. 2012;31(5):572-4.

Fine J, Weissman J, Finestone SC. Side effects after ketamine anesthesia: transient blindness, AnesthAnalg. 1974;53:72-4.

Drayna PC, Estrada C, Wang W. Ketamine sedation is not associated with clinically meaningful elevation of intraocularpressure, Am J Emerg Med. 2012;30(7):1215-8.

Fantinati S, Casarotto R. Bilateral retrobulbar neuritis after general anesthesia, Ann Ophthalmol. 1988;114:649.

Ameen H. Can propofol cause keratitis? Anaesthesia. 2001;56:1017-8.

Neel S, Deitch R, Moorthy SS. Changes in intraocular pressure during low dose intravenous sedation with propofol before cataract surgery. Br J Ophthalmol. 1995;79:1093-7.

Reddy MB. Can propofol cause keratitis? Anesthesia. 2002;57:183-208.

Ghosheh FR, Ehlers JP, Ayres BD. Corneal ulcers associated with aerosolized crack cocaine use. Cornea. 2007;26:966-9.

Lemagne JM, Michiels X, Van Causenbroeck S. Purtscher-like retinopathy after retrobulbar anesthesia, Ophthalmol. 1990;97(7):859-61.

Sawyer RJ, von Schroeder H. Temporary bilateral blindness after acute lidocaine toxicity, AnesthAnalg. 2002;95:224-6.

Han SK, Kim JH, Hwang J-M. Persistent diplopia after retrobulbar anesthesia, J Cataract Refract Surg. 2004;30:1248-53.

Robinson R, White M, McCann P. Effect of anesthesia on intraocular blood flow. Br J Ophthalmol. 1993;75:92-3.

Eldor J, Admoni M. Acute glaucoma following nonophthalmic surgery, Isr J Med Sci. 1989;25:293-4.

Jaanus SD. Ocular side effects of selected systemic drugs. OptomClin. 1992;2:73-96.

Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS drugs. 2010;24:501-26.

Ghosh S, Bhutan D. Oculogyric crisis with quetiapine: a case report. 14th World Congress of Psychiatry 894 abstr. 2008;1-168.

Yong KC, Kah TA, Ghee YT. Branch retinal vein occlusion associated with quetiapine fumarate. BMC Ophthalmol. 2011;11(1):24.

Kanaski JJ. Clinical diagnosis in ophthal. Elsevier. 2006.

Cotliar JM, Shields CL, Meyer DR. Chronic orbital inflammation and fibrosis after retrobulbar alcohol and chlorpromazine injections in a patient with choroidal melanoma, Ophthal Plast Reconstr Surg. 2008;24(5):410-1.

Isaac NE, Walker AM, Jick H. Exposure to phenothiazine drugs and risk of cataract, Arch Ophthalmol. 1991;109:256-60.

Physician’s Desk Reference, ed 60, Montvale NJ. Thomson PDR. 2006;2124-5.

Firht AY. Ocular sequelae from the illicit use of class A drugs. Br I Orthop J. 2004;1:10-8.

Abraham HD: A chronic impairment of colour vision in users of LSD, Br J Psychiatry. 1982;140:518-20.

Kawasaki A, Purvin V. Persistent palinopsia following ingestion of lysergic acid diethylamide (LSD), Arch Ophthalmol. 1996;114:47-50.

Halpern JH, Pope HG. Hallucinogen persisting perception disorder: what do we know after 50 years?, Drug Alcohol Depend. 2003;69:109-19.

Cox D, Jufer Phipps RA, Levine B. Distribution of phencyclidine into vitreous humor, J Anal Toxicol. 2007;31(8):537-9.

Kumar RS, Grigg John, Farinelli AC. Ecstasy induced acute bilateral angle closure and transient myopia. Br J Ophthalmol. 2007;91:693-5.

Huestegge L, Kunert HJ, Radach R. Long-term effects of cannabis on eyemovement control reading, Psychopharmacol. 2010;209(1):77-84.

Levi L, Miller NR. Visual illusions associated with previous drug abuse,FClin Neuro-ophthalmol. 1990;10:103-10.

Semple DM, Ramsden F, McIntosh AM. Reduced binocular depthinversion in regular cannabis users, PharmacolBiochemBehav. 2003;25:789-93.

Hiroz CA, Assimacopoulos T, Cuendet JF, Calanca A, Carron R. [Ophthalmological side effects of lithium (author's transl)]. L'Encephale. 1981;7:123-8.

Fraunfelder FT, Fraunfelder FW, Jefferson JW. Monograph: the effects oflithium on the human visual system, J Toxicol Cut Ocular Toxicol. 1992;11:97-169.

Fraunfelder FT, Fraunfelder FW, Chambers WA. Clinical Ocular Toxicology: Drug-Induced Ocular Side Effects. Philadelphia, USA: Elsevier Health Sciences. 2008.

Varatharaj A, Moran J. Pendularnystagmus associated with venlafaxine overdose: a formefruste of the serotonin syndrome?. BMJ Case Rep. 2014;1-2.

Hughes MS, Lessell S. Trazodone-induced palinopsia, Arch Ophthalmol. 1990;108:399-400.

Chi-un P, Chang-uk L, Soo-Jung L. Association of low dose trazodone treatment with aggravated angle-closure glaucoma, Psychiatry ClinNeurosci. 2003;57:127-9.

Pae C-U, Lee C-U, See S-J. Association of low dose trazodone treatment with aggravated angle-closure glaucoma, Psych Clin Neuros. 2003;57:127-8.

Melinder A, Konijnenberg C, Sarfi M. Deviant smooth pursuit in preschool children exposed prenatally to methadone or buprenorphine and tobacco affects integrative visuomotor capabilities. Addiction. 2013;108:2175-82.

Bonfiglio V, Bucolo C, Camillieri G, Drago F. Possible involvement of nitric oxide in morphine-induced miosis and reduction of intraocular pressure in rabbits. Eur J Pharmacol. 2006;534:227-32.

El-Mallakh RS. Internuclear ophthalmoplegia with narcotic overdosage, Ann Neurol. 1986;20:107.

Nomof N, Elliott HW, Parker KD. The local effect of morphine, nalorphine, and codeine on the diameter of the pupil of the eye, ClinPharmacolTher. 1968;9:358-64.

De Cuyper C, Goeteyn M. Systemic contact dermatitis from subcutaneous hydromorphone, Contact Dermatitis. 1992;27(4):220-3.

Gilman AG, Goodman LS, Gilman A, editors. The Pharmacological Basis of Therapeutics, ed 6, New York, 1980, Macmillan. 1980;495-511.

Firth AY. Heroin and diplopia. Addiction. 2005;100:46-50.

Rizzo M, Corbett J. Bilateral internuclear ophthalmoplegia reversed by naloxone, Arch Neurol. 1983;40:242-3.

Firth AY. Heroin and diplopia. Addiction 200;100:46-50.

Fish DJ, Rosen SM. Epidural opioids as a cause of vertical nystagmus. Anesthesiology. 1990;73:785-6.

Henderson RD, Wijdicks EF. Downbeat nystagmus associated with intravenous patient-controlled administration of morphine. AnesthAnalg. 2000;91:691-2.

Castano G, Lyons CJ. Eyelid pruritus with intravenous morphine, J AmAssocPediatrOphthalmol Strabismus. 1999;3(1):60.

Gupta M, Mulvihill AO, Lascaratos G. Nystagmus and reducedvisual acuity secondary to drug exposure in utero: long-term followup. J Ped Ophthalmol Strab. 2012;49(1):58-63.

Hamilton R, McGlone L, MacKinnon JR. Ophthalmic, clinical andvisual electrophysiological findings in children born to mothersprescribed substitute methadone in pregnancy, Br J Ophthalmol. 2010;94:696-700.

Nelson LB, Ehrlich S, Calhoun JH. Occurrence of strabismus in infants born to drug-dependent women, Am J Dis Child. 1987;141:175-8.

Rizzo M, Corbett J. Bilateral internuclear ophthalmoplegia reversed by naloxone. Arch Neurol. 1983;40:242-3.

Burstein AH, Fullerton T. Oculogyric crisis possibly related to pentazocine. Ann Pharm. 1983;27(7–8):874-6.

Waisbren BA, Smith MB. Hypersensitivity to meperidine. JAMA. 1978;239:1395.

Monastero R, Camarda C, Pipia C, Camarda R. Visual hallucinations and agitation in alzheimer’s disease due to Memantine: report of three cases. J Neurology Neurosurgery and Psychiatry. 2006;78: 546.

Anwar A, Gutting P. Potentiation of warfarin’s anticoagulant effect and subconjunctival haemorrhage with rivastigmine transdermal patch. BMJ Case reports. 2010;10:1136.

Vijayakumar AR, Velpandian T, Saxena R. Ocular adverse effects of systemically administered drugs. In: Renu Agarwal, Puneet Agarwal, editors. Essential of Ocular Pharmacology, 1stedn. Malaysia: University Publication Centre (UPENA). 2011;343-64.